CN Patent

CN104127878A — 结合配体连接的微管溶素递药缀合物

Assigned to Endocyte Inc · Expires 2014-11-05 · 12y expired

What this patent protects

本申请描述了用于治疗致病细胞群体的化合物、药物组合物和方法。本申请特别涉及结合配体连接的微管溶素递药缀合物。本申请所述化合物包括微管溶素和维生素受体结合配体的缀合物。所述缀合物还包括可释放的二价接头。

USPTO Abstract

本申请描述了用于治疗致病细胞群体的化合物、药物组合物和方法。本申请特别涉及结合配体连接的微管溶素递药缀合物。本申请所述化合物包括微管溶素和维生素受体结合配体的缀合物。所述缀合物还包括可释放的二价接头。

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: CN104127878A
Jurisdiction: CN
Classification: —
Expires: 2014-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Endocyte Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.